Rx-360 summary of FDA Final Guidance Refuse to Accept Policy for 510(k)s
Rx-360 has releases a summary of FDA Final Guidance Refuse to Accept Policy for 510(k)s.
FDA has published a revised final guidance document entitled "Refuse to Accept Policy for 510(k)s," which will go into effect on 1 October 2015. This guidance will replace the prior version of the guidance issued on 31 December 2012. The purpose of the guidance is to describe FDA's initial screening process for 510(k) submissions, which is used to determine if the submission is sufficiently complete to undergo substantive review. The guidance has been updated to incorporate internal FDA and stakeholder feedback on the implementation of the "Refuse to Accept" (RTA) process.
Key revisions include
(i) streamlining of checklists to reflect actual review practice, additional flexibility to permit reviewer discretion to accept files lacking certain non-critical information
(ii) incorporation of guidance issued since the release of the prior version (e.g., recently issued device reprocessing guidance)
(iii) addition of a page number column for industry to identify the location of required elements in the submission
(iv) revisions to checklist items that could lead to substantive review during the screening process (i.e., to ensure only administrative review occurs during the screening process).
In addition, this version makes clear that FDA encourages submitters to complete and submit the relevant acceptance checklist with their submission to identify the location of supporting information for each RTA element.
This guidance document supersedes three existing guidance documents titled "Refuse to Accept Policy for 510(k)s" issued on 31 December 2012; "Center for Devices and Radiological Health's Premarket Notification (510(k)) Refuse to Accept Policy" issued on 30 June 30 1993; and "510(k) Memorandum K94-1" issued on 20 May 1994.
To view or download the FDA Guidance, click here
Related News
-
News PSCI Welcomes Delpharm, Samsung Biologics, and Suven as First Supplier Partners
The pharmaceutical industry continues to evolve with an increasing focus on responsible sourcing, sustainability, and collaboration across the supply chain. Under a new model to recognise suppliers within the pharmaceutical and healthcare industry that... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News Eisai Alzheimer’s drug authorised in UK but still faces obstacles
In partnership with BioArctic AB, pharmaceutical company Eisai has been granted Marketing Authorisation by the Medicines and Healthcare products Regulatory Agency (MHRA) for its Alzheimer’s disease drug product Leqembi. -
News Eli Lilly's weight loss drugs removed from the FDA's shortage list
The US FDA have recently updated their drug shortage list. The recently released list shows that all dosage forms of Eli Lilly's weight-loss drug Zepbound and their diabetes drug Mounjaro are now available. -
News Global advancements in the diagnosis and treatment of rare diseases: Rare Disease Day 2024
Rare Diseases Day is celebrated on the 29th February 2024 and represents the plight of rare disease patients to gain diagnosis and access to suitable treatment. -
News Pharmaceutical industry supports COP28 health stance in joint statement
As COP28 takes place over this week in Dubai, UAE, several bodies in the pharmaceutical and health industries have come together to announce support of key movements in sustainability in the sector, and to recognise sustainability as a health issue.&nb... -
News Biden backs Cold-War measures to shore-up medical supply chains
In a recent strategy to combat rising inflation and the cost of living crisis, President Joe Biden has invoked a Cold War-era act to increase investment in a selection of medicines and supplies. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance